Amgen and Simcere strike a deal to co-develop four biosimilars in China
By David Ho
Staff Writer
Staff Writer
Wednesday, September 27, 2017
HONG KONG Amgen Inc. and Simcere Pharmaceutical Group have entered into an agreement to develop and commercialize four biosimilars for the Chinese market.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.